Press release
Focal Segmental Glomerulosclerosis Treatment Market Size Report 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Compa
Focal Segmental Glomerulosclerosis Market
Discover Key Insights into the Focal Segmental Glomerulosclerosis Market with DelveInsight's In-Depth Report @ Focal Segmental Glomerulosclerosis Market Size- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report
• In February 2025:- Sanofi announced a study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years.
• In February 2025:- Boehringer Ingelheim conducted a study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study.
• The overall count of individuals diagnosed with Focal Segmental Glomerulosclerosis in the United States was approximately 26 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
• Among the 7MM, Japan accounted for the highest number of Focal Segmental Glomerulosclerosis diagnosed cases of around 8 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
• Among EU4 and the UK, Germany had the highest Focal Segmental Glomerulosclerosis diagnosed prevalent population, with about 5 million cases, followed by France and Italy in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• In 2022, DelveInsight's analysis of Focal Segmental Glomerulosclerosis gender-specific diagnosed prevalent cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
• The leading Focal Segmental Glomerulosclerosis Companies such as Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
• Promising Focal Segmental Glomerulosclerosis Therapies such as DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
Stay ahead in the Focal Segmental Glomerulosclerosis Therapeutics Market with DelveInsight's Strategic Report @ Focal Segmental Glomerulosclerosis Market Outlook- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Focal Segmental Glomerulosclerosis Epidemiology Segmentation in the 7MM
• Total Focal Segmental Glomerulosclerosis Diagnosed Prevalent Cases
• Focal Segmental Glomerulosclerosis Gender-specific Cases
• Diagnosed Prevalent Cases
• Focal Segmental Glomerulosclerosis Age-specific Diagnosed Prevalent Cases
• Focal Segmental Glomerulosclerosis Comorbodity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis Epidemiology trends @ Focal Segmental Glomerulosclerosis Prevalence- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Focal Segmental Glomerulosclerosis Marketed Drugs
• LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation. LEQVIO, the sole approved FSGS treatment in United States and Europe with an active patent, dominates the FSGS treatment landscape, immune to biosimilar competition.
Focal Segmental Glomerulosclerosis Emerging Drugs
• Olpasiran (AMG 890): Amgen Inc.
Olpasiran (AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a). It is being investigated for treating FSGS; the drug is administered subcutaneously as a solution. Olpasiran is currently in Phase III clinical trial in participants with FSGS and elevated lipoprotein (a). The absence of approved alternatives highlights the potential for Olpasiran to contribute significantly to the expansion of the FSGS treatment market.
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis. FSGS is influenced by genetic predisposition, lifestyle factors, and comorbidities. Strategies vary depending on the severity of the disease, aiming to curb FSGS. Treatment for FSGS starts with a change in lifestyle that includes stress management, regular exercise, dietary adjustments, and quitting smoking. Their potential to supplement pharmaceutical therapies and effectively lower cardiovascular risk factors is highlighted by a thorough examination of their influence on patient outcomes.
Get In-Depth Knowledge on Focal Segmental Glomerulosclerosis Market Trends and Forecasts with DelveInsight @ Focal Segmental Glomerulosclerosis Treatment Market- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Focal Segmental Glomerulosclerosis Treatment Market
As the Focal Segmental Glomerulosclerosis Treatment Market Landscape evolves, the emergence of Olpasiran in a Phase III trial brings hope for a targeted therapeutic option. The projected introduction of Olpasiran for FSGS is anticipated to propel the overall FSGS market in the 7MM, potentially reaching nearly USD 837 million by 2034.
Scope of the Focal Segmental Glomerulosclerosis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Focal Segmental Glomerulosclerosis Companies- Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
• Focal Segmental Glomerulosclerosis Therapies- DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
• Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight's Comprehensive Focal Segmental Glomerulosclerosis Market Report @ Focal Segmental Glomerulosclerosis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1 Key Insights
2 Report Introduction
3 Focal Segmental Glomerulosclerosis (FSGS) Market Overview by Therapies
4 Methodology of Focal Segmental Glomerulosclerosis Epidemiology and Market
5 Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)
6 Key Events
7 Focal Segmental Glomerulosclerosis Disease Background and Overview: FSGS
8 Focal Segmental Glomerulosclerosis Epidemiology and Patient Population
9 Focal Segmental Glomerulosclerosis Patient Journey
10 Focal Segmental Glomerulosclerosis Marketed Drugs
11 Focal Segmental Glomerulosclerosis Emerging Drugs
12 Focal Segmental Glomerulosclerosis Market Analysis
13 Key Opinion Leaders' Views
14 Focal Segmental Glomerulosclerosis SWOT Analysis
15 Focal Segmental Glomerulosclerosis Unmet Needs
16 Focal Segmental Glomerulosclerosis Market Access and Reimbursement
17 Appendix
18 Focal Segmental Glomerulosclerosis Market Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
List of Top Selling Market Research Reports in 2025
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Treatment Market Size Report 2034 | Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Compa here
News-ID: 3910440 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Focal
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
Display Chips Market | Analogix, Focal Tech, Himax Technologies, MegaChips
The global display chips market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the display chips market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
